A multicenter study led by Prof. Shuixing Zhang and Prof. Bin Zhang from the First Affiliated Hospital of Jinan University enrolled 246 patients with locally advanced NPC treated with immunotherapy. By applying artificial intelligence algorithms, the team extracted and selected optimal radiomic features from medical imaging to construct a predictive model.

A trailblazing Genomic Press interview with Dr. Bruce M. Cohen explores how cutting-edge brain cell technology is providing revolutionary new information on the biological origins of psychiatric disorders. Among these findings, the Harvard professor discusses discoveries on mitochondrial dysfunction that are opening novel therapeutic pathways for schizophrenia, bipolar disorder, and Alzheimer disease. In addition, his advocacy for evidence-based diagnostic models challenges century-old psychiatric frameworks, proposing specific dimensional approaches that better capture the complexities of causes, presentations, and outcomes of mental illnesses.

Researchers at the University Medical Center Göttingen, Germany, have discovered that heart rate deceleration within the first 45 seconds of brain stimulation predicts treatment success in major depression up to six weeks later. The study of 75 patients found that monitoring cardiac responses during transcranial magnetic stimulation could help clinicians identify which patients will benefit most from treatment. Roberto Goya-Maldonado and colleagues at the University Medical Center Göttingen published these findings, demonstrating a potential biomarker for personalizing depression therapy.

A groundbreaking Genomic Press interview explores Dr. Najaf Amin's innovative approach to depression genetics at Oxford University. The internationally acclaimed researcher has identified novel metabolites, rare gene variants, and systemic pathways that expand current understanding of depression's biological underpinnings. Her discoveries, including the RCL1 gene mutation, 124 depression-linked metabolites and 13 types of gut bacteria, provide new insights into the multifactorial nature of this prevalent psychiatric disorder and suggest potential avenues for more targeted therapeutic approaches.

A comprehensive peer-reviewed invited review published in Psychedelics examines the therapeutic potential of MDMA across psychiatric conditions, synthesizing evidence from PTSD trials to emerging applications in autism and eating disorders. The authors identify gut-brain axis mechanisms underlying resilience enhancement while addressing critical safety considerations including hyponatremia and neurotoxicity risks. This synthesis provides clinicians and researchers with an integrated framework for understanding MDMA-assisted therapy as regulatory decisions evolve.